Your browser doesn't support javascript.
loading
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT.
Spyridonidis, Alexandros; Labopin, Myriam; Savani, Bipin; Giebel, Sebastian; Bug, Gesine; Schönland, Stefan; Kröger, Nicolaus; Stelljes, Matthias; Schroeder, Thomas; McDonald, Andrew; Blau, Igor-Wolfgang; Bornhäuser, Martin; Rovira, Montse; Bethge, Wolfgang; Neubauer, Andreas; Ganser, Arnold; Bourhis, Jean Henri; Edinger, Matthias; Lioure, Bruno; Wulf, Gerald; Schäfer-Eckart, Kerstin; Arat, Mutlu; Peric, Zinaida; Schmid, Christoph; Bazarbachi, Ali; Ciceri, Fabio; Nagler, Arnon; Mohty, Mohamad.
Affiliation
  • Spyridonidis A; Bone Marrow Transplantation Unit and Institute of Cellular Therapy, University of Patras, Greece.
  • Labopin M; Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
  • Savani B; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Giebel S; Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
  • Bug G; Department of Medicine II, Hematology, Medical Oncology, Goethe-University, Frankfurt, Germany.
  • Schönland S; Medical Department V, University Hospital Heidelberg, Germany.
  • Kröger N; Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany.
  • Stelljes M; Department of Hematology/Oncology, University of Muenster, Germany.
  • Schroeder T; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
  • McDonald A; Alberts Cellular Therapy, Netcare Pretoria East Hospital, South Africa.
  • Blau IW; Charité Universitätsmedizin Berlin, Germany.
  • Bornhäuser M; University Hospital, TU Dresden, Germany.
  • Rovira M; BMT Unit, Hematology Department, Institute of Hematology & Oncology, Josep Carreras Institute, Barcelona, Spain.
  • Bethge W; Department of Hematology & Oncology, University Hospital Tuebingen, Medical Center, Tuebingen, Germany.
  • Neubauer A; Philipps Universitaet Marburg, University of Hospital Giessen and Marburg, Germany.
  • Ganser A; Hannover Medical School, Germany.
  • Bourhis JH; Gustave Roussy Cancer Campus BMT, Department of Hematology, Villejuif, France.
  • Edinger M; Department of Hematology and Oncology, University Regensburg, Germany.
  • Lioure B; Hematology, Stem Cell Transplant Unit, ICANS, Strasbourg, France.
  • Wulf G; University Medicine Goettingen, Hematology and Medical Oncology, Goettingen, Germany.
  • Schäfer-Eckart K; Klinikum Nuernberg, 5. Medizinische Klinik, BMT-Unit, Nuernberg, Germany.
  • Arat M; Demiroglu Bilim Univ. Istanbul Florence Nightingale Hospital, Istanbul, Turkey.
  • Peric Z; University Hospital Centre, Zagreb, Croatia.
  • Schmid C; Universitatsklinikum Augsburg, Section Stem Cell Transplantation, Augsburg University and Medical Faculty, Germany.
  • Bazarbachi A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut-Medical Center, Beirut, Lebanon.
  • Ciceri F; Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy.
  • Nagler A; Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
  • Mohty M; Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France.
Hemasphere ; 7(1): e812, 2023 Jan.
Article in En | MEDLINE | ID: mdl-36698616
ABSTRACT
In this registry-based study, we compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) transplanted in first complete remission (CR-1), following conditioning with total body irradiation (TBI) at a standard 12-Gray or at a lower 8-Gray total dose. Patients received fludarabine (flu) as the sole chemotherapy complementing TBI. Eight-Gray TBI/flu was used in 494 patients and 12-Gray TBI/flu in 145 patients. Eighty-eight (23.1%) and 36 (29%) of the patients had Ph-negative B-ALL, 222 (58.3%) and 53 (42.7%) had Ph-positive B-ALL, 71 (18.6%) and 35 (28.2%) T-ALL, respectively (P = 0.008). Patients treated with 8-Gray were older than ones received 12-Gray (median 55.7 versus 40.3 years, P < 0.0001) and were more frequently administered in vivo T-cell depletion (71% versus 40%, P <0.0001). In a multivariate model adjusted for age, type of ALL, and other prognostic factors, leukemia-free survival (primary endpoint) as well as relapse, nonrelapse mortality, overall survival, and GVHD-free, relapse-free survival were not influenced by the TBI dose. These results were confirmed when we focused on patients <55 years of age (median 47 years). Patients with Ph-positive ALL or T-ALL had significantly better survival outcomes than ones with Ph-negative B-ALL, mainly due to significantly fewer relapses. We conclude that 8-Gray TBI is sufficient for adult patients with ALL transplanted in CR-1 with no additional benefit of augmenting the conditioning intensity to 12-Gray.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Hemasphere Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Hemasphere Year: 2023 Document type: Article Affiliation country: